1-Methyl-4-(pyrrolidin-2-yl)piperidine → 2-(3-methyl-5-(9-(2-(1-methylpiperidin-4-yl)pyrrolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-2-yl)-1H-1,2,4-triazol-1-yl)ethanol

HRID 1530625Notes

Reaction equation

HRID 1530625 reaction equation
Br[C:2]1[CH:3]=[C:4]2[C:13](=[CH:14][CH:15]=1)[C:12]1[N:8]([CH:9]=[C:10]([C:16]3[N:20]([CH2:21][CH2:22][OH:23])[N:19]=[C:18]([CH3:24])[N:17]=3)[N:11]=1)[CH2:7][CH2:6][O:5]2.[CH3:25][N:26]1[CH2:31][CH2:30][CH:29]([CH:32]2[CH2:36][CH2:35][CH2:34][NH:33]2)[CH2:28][CH2:27]1.CC(C1C=C(C(C)C)C(C2C=CC=CC=2P(C2CCCCC2)C2CCCCC2)=C(C(C)C)C=1)C.C(O[Na])(C)(C)C>O1CCOCC1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[CH3:24][C:18]1[N:17]=[C:16]([C:10]2[N:11]=[C:12]3[C:13]4[CH:14]=[CH:15][C:2]([N:33]5[CH2:34][CH2:35][CH2:36][CH:32]5[CH:29]5[CH2:28][CH2:27][N:26]([CH3:25])[CH2:31][CH2:30]5)=[CH:3][C:4]=4[O:5][CH2:6][CH2:7][N:8]3[CH:9]=2)[N:20]([CH2:21][CH2:22][OH:23])[N:19]=1

Participants

7

Reactant 4

HCID 45663131-Methyl-4-(pyrrolidin-2-yl)piperidineHCID 111557942-Dicyclohexylphosphino-2',4',6'-triisoprophylbiphenylHCID 683128562-(5-{12-bromo-9-oxa-3,6-diazatricyclo[8.4.0.02,6]tetradeca-1(14),2,4,10,12-pentaen-4-yl}-3-methyl-1H-1,2,4-triazol-1-yl)ethan-1-olHCID 178418730sodium 2-methylpropan-2-olate

Product 1

HCID 665587642-(3-methyl-5-(9-(2-(1-methylpiperidin-4-yl)pyrrolidin-1-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-2-yl)-1H-1,2,4-triazol-1-yl)ethanolYield 4%

Reagents, catalysts & solvents 2

HCID 9811564Bis(dibenzylideneacetone)palladiumCatalystHCID 312751,4-DioxaneSolvent

Conditions

Temperature
100 °C

Procedure

A mixture of 2-(5-{12-bromo-9-oxa-3,6-diazatricyclo[8.4.0.02,6]tetradeca-1(14),2,4,10,12-pentaen-4-yl}-3-methyl-1H-1,2,4-triazol-1-yl)ethan-1-ol (80.0 mg, 0.206 mmol), 1-methyl-4-(pyrrolidin-2-yl)piperidine (41.5 mg, 0.247 mmol), Pd2(dba)3 (9.4 mg, 0.010 mmol), Xphos (9.8 mg, 0.021 mmol), and t-BuONa (59.3 mg, 0.618 mmol) in dioxane (10 ml) was degassed with N2 3 times. The resulting mixture was sealed in a microwave vial and stirred at 100° C. overnight. The solid was filtered off. The filtrate was concentrated to give the crude product, which was purified by prep-HPLC (Gilson GX 281, Shim-pack PRC-ODS 250 mm×20 mm×2, gradient: CH3CN/10 mm/L NH4HCO3, 17 min) to afford 237 (3.5 mg, 4% yield) as an off white solid. LCMS (ESI): RT=4.03 min, m/z: 478.4 [M+H+]. 1H NMR (500 MHz, MeOD-d4) δ 8.40 (m, 1H), 8.10-8.09 (d, J=8.5 Hz, 1H), 7.56 (s, 1H), 6.44-6.42 (dd, J=9.0, 2.0 Hz, 1H), 6.17 (d, J=2.5 Hz, 1H), 4.68-4.66 (m, 2H), 4.37-4.32 (m, 4H), 3.93-3.91 (t, J=5.5 Hz, 2H), 3.79-3.76 (m, 1H), 3.46-3.37 (m, 3H), 3.17-3.12 (m, 1H), 2.82 (m, 1H), 2.69 (s, 3H), 2.26 (s, 3H), 1.99-1.82 (m, 6H), 1.73-1.70 (m, 1H), 1.56-1.51 (m, 2H), 1.23-1.19 (m, 2H)

Workup

  1. customwas degassed with N2 3 times
  2. customThe resulting mixture was sealed in a microwave vial
  3. filtrationThe solid was filtered off
  4. concentrationThe filtrate was concentrated
  5. customto give the crude product, which
  6. customwas purified by prep-HPLC (Gilson GX 281, Shim-pack PRC-ODS 250 mm×20 mm×2, gradient: CH3CN/10 mm/L NH4HCO3, 17 min)

Sources & evidence

ORD record
ord-2c40ef4e21b64a939185a464b6bcf9c2
Source dataset
uspto-grants-2015_07
Patent number
US09090628B2

Reaction notes

Loading…